Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD) groups product licence applications into three classes based primarily on how NNHPD monographs are used. These are application classes—not product risk classes.
The regulatory pathway is shaped by the product’s ingredients, dosage form, route of administration, recommended conditions of use, claims, supporting evidence, and whether Health Canada monographs can be used. A formula that appears straightforward commercially can become a complex regulatory project when the proposed claim, ingredient combination, dose, source material, or evidence falls outside established monograph parameters.
A well-planned Natural Health Product consulting strategy aligns product classification, formulation, evidence, licensing, quality, labelling, and market-entry requirements before they become launch delays or costly corrective work.
The practical scope is broad. Health Canada’s current GMP guidance covers non-sterile NHPs such as enzymes, probiotics, amino acids, herbal remedies, essential fatty acids, traditional medicines, vitamins and minerals, and certain products such as toothpastes, antiperspirants, shampoos, facial products, and mouthwashes. It also covers sterile NHPs, including ophthalmic products and sterile water for irrigation, as well as homeopathic medicines.
For companies without dedicated in-house regulatory resources, an experienced NHP consultant can help connect these requirements into one practical market-access plan.
Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD) groups product licence applications into three classes based primarily on how NNHPD monographs are used. These are application classes—not product risk classes.
| Pathway | Typical Fit | Evidence / Review | Current Service Standard |
|---|---|---|---|
| Class I | Fully complies with every parameter of a single NNHPD monograph. | Compendial pathway; no deviation from the selected monograph. | 60 calendar days |
| Class II | Supported by applicable NNHPD monographs but does not fit the strict Class I single-monograph pathway. | NNHPD verifies the application against the monographs attested to. | 90 calendar days |
| Class III | Requires assessment beyond monograph support—for example, evidence for safety and/or efficacy outside established monograph parameters. | Comprehensive regulatory assessment may be required. | 210 calendar days |
Choosing the right class early matters. An incorrect class, incomplete monograph attestation, missing evidence, or unsupported claim can create screening issues, information requests, or refusal risk. dicentra can assess the product against current monographs and evidence requirements before filing.
For unique claims, early evidence planning can help avoid building a commercial concept that cannot be supported at the intended regulatory threshold.
Speak with our Natural Health Product consultants about your product, evidence, licensing, quality, or market-access requirements.
The Natural Health Products Regulations define an NHP by both what it contains and how it is represented for use. Schedule 1 includes categories such as plant and plant materials, algae, bacteria, fungi, certain non-human animal materials, extracts and isolates, specified vitamins, amino acids, essential fatty acids, certain synthetic duplicates, minerals, and probiotics. Homeopathic and traditional medicines can also fall within the definition. Schedule 2 substances are excluded.
Generally, yes. The Regulations prohibit the sale of a Natural Health Product unless a product licence has been issued for it, subject to limited regulatory exceptions. Once licensed, the product is assigned a product number; most NHPs receive an NPN, while homeopathic medicines may receive a DIN-HM.
An NPN, or Natural Product Number, is the product number Health Canada assigns to a licensed Natural Health Product. It identifies a product that has completed the applicable product licensing process and is authorized for sale under its approved conditions.
They are Health Canada application classes based on how NNHPD monographs are used. Class I applications must fully match a single monograph. Class II applications rely on applicable monograph support but do not fit the strict Class I pathway. Class III applications require assessment beyond monograph support, such as additional safety or efficacy evidence. These are application classes, not product risk classes.
Health Canada’s current NHP Management of Applications Policy lists service standards of 60 calendar days for Class I, 90 calendar days for Class II, and 210 calendar days for Class III applications. Actual project timing can also be affected by application readiness, screening issues, information requests, prioritization, and the completeness of the supporting package.
A product licence application must contain information demonstrating safety and efficacy when the product is used according to its recommended conditions of use. Depending on the application, this may be supported by NNHPD monographs, other acceptable evidence, or a combination of both. More novel claims, ingredients, doses, combinations, or uses can require a more extensive evidence package.
NHPs can be authorized with health-related recommended uses or purposes when the evidence supports them and the wording is acceptable to Health Canada. The proposed claim is a major part of the licensing strategy because it affects the evidence needed and may determine whether a monograph-based pathway is available.
A site licence is required for Canadian sites that manufacture, package, label, or import NHPs for sale. Distributors have applicable GMP responsibilities, although distribution by itself is not one of the activities listed in the site-licence prohibition.
Part 3 of the Natural Health Products Regulations establishes GMP requirements covering areas such as specifications, premises, equipment, personnel, sanitation, operations, quality assurance, stability, and records. The requirements apply across the regulated supply chain according to the activities performed.
Sterile NHPs remain subject to the Natural Health Products Regulations, but additional GMP controls apply. Products intended to be sterile must be manufactured and packaged under specified conditions designed to ensure sterility. Health Canada’s GMP guidance identifies ophthalmic products and sterile water for irrigation as examples of sterile NHPs.
Certain products in these categories can fall within the NHP framework, but the product must meet the legal definition and applicable classification requirements. Product format alone does not determine NHP status, so classification should be assessed based on ingredients, intended use, claims, and the regulatory framework.
Yes, but the Canadian regulatory and quality infrastructure must be addressed. The product requires the applicable Canadian product licence, and importation for sale is a site-licensed activity. Foreign manufacturing, packaging, and labelling sites must also be supported by acceptable GMP evidence through the Canadian site-licensing framework.
Clinical trials may be used to generate product-specific safety or efficacy evidence, support new or stronger claims, investigate dosing, or advance a development program. Clinical trials involving NHPs are governed by Part 4 of the Natural Health Products Regulations and require the applicable Health Canada authorization before the trial begins.
Compliance continues after authorization. Depending on the change, licence holders may need to file an amendment or notification. Companies also have ongoing obligations related to GMP, records, complaints, recalls, safety information, and adverse reaction reporting.
An NHP consultant can help connect classification, claims, evidence, product licensing, site licensing, GMP, labelling, importation, and post-market obligations into one regulatory strategy. This is especially useful for novel products, unique claims, international market entry, complex supply chains, or companies without dedicated Canadian regulatory resources.